Eikon Therapeutics Statistics
Total Valuation
EIKN has a market cap or net worth of $324.03 million. The enterprise value is $111.86 million.
| Market Cap | 324.03M |
| Enterprise Value | 111.86M |
Important Dates
The last earnings date was Thursday, November 12, 2026, before market open.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
EIKN has 54.19 million shares outstanding. The number of shares has increased by 1,194.24% in one year.
| Current Share Class | 54.19M |
| Shares Outstanding | 54.19M |
| Shares Change (YoY) | +1,194.24% |
| Shares Change (QoQ) | +0.05% |
| Owned by Insiders (%) | 6.26% |
| Owned by Institutions (%) | 53.22% |
| Float | 33.46M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.84 |
| P/TBV Ratio | 0.84 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.21, with a Debt / Equity ratio of 0.65.
| Current Ratio | 7.21 |
| Quick Ratio | 6.97 |
| Debt / Equity | 0.65 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -423.23 |
Financial Efficiency
Return on equity (ROE) is -90.94% and return on invested capital (ROIC) is -35.95%.
| Return on Equity (ROE) | -90.94% |
| Return on Assets (ROA) | -32.84% |
| Return on Invested Capital (ROIC) | -35.95% |
| Return on Capital Employed (ROCE) | -55.36% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$877,953 |
| Employee Count | 384 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 7.53 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 42.91 |
| Average Volume (20 Days) | 541,527 |
Short Selling Information
The latest short interest is 5.54 million, so 10.22% of the outstanding shares have been sold short.
| Short Interest | 5.54M |
| Short Previous Month | 6.37M |
| Short % of Shares Out | 10.22% |
| Short % of Float | 16.55% |
| Short Ratio (days to cover) | 9.85 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -354.25M |
| Pretax Income | -337.13M |
| Net Income | -337.13M |
| EBITDA | -333.48M |
| EBIT | -354.25M |
| Earnings Per Share (EPS) | -$9.28 |
Balance Sheet
The company has $461.72 million in cash and $249.55 million in debt, with a net cash position of $212.17 million or $3.92 per share.
| Cash & Cash Equivalents | 461.72M |
| Total Debt | 249.55M |
| Net Cash | 212.17M |
| Net Cash Per Share | $3.92 |
| Equity (Book Value) | 384.29M |
| Book Value Per Share | 7.09 |
| Working Capital | 411.85M |
Cash Flow
In the last 12 months, operating cash flow was -$265.67 million and capital expenditures -$998,000, giving a free cash flow of -$266.67 million.
| Operating Cash Flow | -265.67M |
| Capital Expenditures | -998,000 |
| Depreciation & Amortization | 20.77M |
| Net Borrowing | n/a |
| Free Cash Flow | -266.67M |
| FCF Per Share | -$4.92 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
EIKN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1,194.24% |
| Shareholder Yield | -1,194.24% |
| Earnings Yield | -155.25% |
| FCF Yield | -82.30% |
Analyst Forecast
The average price target for EIKN is $24.33, which is 306.86% higher than the current price. The consensus rating is "Buy".
| Price Target | $24.33 |
| Price Target Difference | 306.86% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |